Pascal Biosciences Inc (TSE:NEVI)
:NEVI
Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.07
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.07
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)55.49K
Market Cap
C$1.19M
Enterprise ValueC$1.23M
Total Cash (Recent Filing)C$102.17K
Total Debt (Recent Filing)C$244.21K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumAccelerating top-line growth demonstrates expanding market traction and productive revenue execution versus recent years. Sustained revenue momentum provides a larger base to absorb fixed costs and supports a path toward profitability if margins stabilize, making future operating leverage more attainable.
Improved Cash GenerationThe move to positive operating and free cash flow signals materially better cash discipline and working-capital management versus prior years. Durable positive cash generation reduces near-term funding pressure and gives management room to invest selectively or extend runway while pursuing profitability.
Declining Leverage/Stronger Balance SheetLower leverage and a positive equity base improve financial flexibility and reduce interest burden, helping the company absorb continued losses while it scales. A healthier balance sheet supports strategic choices and lowers refinancing risk if profitability recovery is gradual but sustained.
Bears Say
Ongoing UnprofitabilityDespite narrowing losses, persistent negative margins mean the business still consumes capital and cannot self-fund growth long-term. Continued unprofitability depresses returns on equity, risks further dilution or debt if extended, and limits reinvestment capacity without structural margin improvement.
Severe Gross Margin CompressionA dramatic gross margin decline indicates either cost inflation, adverse product mix, or execution issues that materially threaten unit economics. Structural margin erosion undermines scalability: even with revenue growth, profitability and cash conversion will be hard to sustain without reversing these pressures.
Small Scale & Modest Cash BaseVery limited operating scale and modest absolute cash generation constrain the firm's ability to invest, absorb shocks, or expand distribution. Small scale raises execution risk, magnifies operational disruptions, and likely necessitates external capital if profitability and cash flow do not continue improving.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$1.19M.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Jul 23, 2026 which is in 33 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Based in Seattle, Washington, Nevis Brands Inc. is engaged in developing and commercializing cannabis products across the United States. Its signature offering is Major, a popular cannabis-infused beverage. The company adopted its current name, Nevis Brands Inc., in June 2023, having previously been known as Pascal Biosciences Inc.
Technical Analysis
TAAT Global Alternatives
―
West Island Brands Inc
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―
Options Prices
Currently, No data available
---